re: Generation

January 10, 2020

What makes Generation Bio unique? Hear from our team.

by GEOFF MCDONOUGH, MD, PRESIDENT & CHIEF EXECUTIVE OFFICER

At Generation Bio, we believe that culture is shaped by everyone in our community — each employee using their unique skills, experiences and personality to help us achieve our collective mission. We view each new employee as bringing their own superpower to the team, enabling us to do something we couldn’t do before or see something from a new perspective. Because we value this emergent culture so highly, we are always taking steps to foster an environment where people can thrive and succeed, and feel comfortable being themselves.

From organizing our open-air seating into planful neighborhoods of cross-sectional employees, to gathering together for weekly, company-wide town halls, to our Friday morning tradition of disco dance parties, we’ve created a truly unique community and culture at Generation Bio that strikes a balance between hard work and fun. Check out the video below to hear from our employees about our culture — and consider joining our generation!

Next article: Penny and Simon take on the world

Safe Harbor Statement: Any statements in this press release about future expectations, plans and prospects for the company, including statements about our strategic plans or objectives, our technology platforms, our research and clinical development plans, the expected timing of the submission of IND applications and preclinical data, our manufacturing plans, our expectations regarding our new facility and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the conduct of research activities, the initiation and completion of preclinical studies and clinical trials and clinical development of the company’s product candidates; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; uncertainties regarding the timing and ability to complete the build-out of the Company’s manufacturing facility and regarding the new manufacturing process; expectations regarding the timing of submission of IND applications; expectations for regulatory approvals to conduct trials or to market products; challenges in the manufacture of genetic medicine products; whether the Company’s cash resources are sufficient to fund the company’s operating expenses and capital expenditure requirements for the period anticipated, including the funding of the new manufacturing facility; the impact of the COVID-19 pandemic on the company’s business and operations; as well as the other risks and uncertainties set forth in the “Risk Factors” section of our most recent annual report on Form 10-K and quarterly report on Form 10-Q, which are on file with the Securities and Exchange Commission, and in subsequent filings the company may make with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the company’s views as of the date hereof. The company anticipates that subsequent events and developments will cause the company’s views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date on which they were made.